Market
Secures exclusive U.S. sales rights for Versius portfolio Agreement also includes option to acquire 100% stake in the future

Stryker invested about $400 million (about 536 billion won) in U.K. surgical robotics company CMR Surgical and secured exclusive U.S. sales rights.
According to U.S. health care trade publication Fierce Biotech on the 14th (local time), Stryker signed a "strategic" investment agreement with CMR Surgical covering surgical robotics technology.
Under the agreement, Stryker will become the exclusive U.S. sales agent for CMR Surgical's Versius surgical robotics portfolio.
Versius is a modular, portable surgical robot designed to help hospitals and physicians expand patient access to minimally invasive surgery.
CMR Surgical, headquartered in the U.K., will continue to lead product development and commercialization in markets outside the United States.
Stryker also secured an exclusive option to acquire 100% of CMR Surgical's issued shares in the future.
The partnership combines CMR Surgical's soft-tissue surgical robotics portfolio and clinical experience with Stryker's scale, customer relationships and commercial execution.
Demand for robot-assisted surgery is increasing worldwide. Procedures performed with da Vinci, the robotic surgery system from U.S. medical device company Intuitive, rose 18% in 2025 from the previous year.
CMR Surgical's Versius has received U.S. Food and Drug Administration (FDA) clearance for cholecystectomy, and the company has also submitted a 510(k) application for benign gynecologic indications.
Andy Pierce, president of Stryker's MedSurg and Neurotechnology Group, said, "Soft-tissue surgical robotics is a high-growth adjacent field and a natural extension of Stryker's strengths in endoscopy, imaging and support technologies."
CMR Surgical CEO Massimiliano Colella said, "This strategic partnership is an important milestone for CMR and a strong endorsement of the technology, clinical experience and global business we have built."
Colella added, "Stryker's investment will provide additional capabilities to accelerate innovation and expand the Versius portfolio globally," and said, "Its scale and deep customer relationships will create significant growth opportunities in the United States."
The agreement comes just days after Stryker announced that company veteran Spencer Stiles would become CEO and former CEO Kevin Lobo would move to the board.

Biobook Team
biobookmedia@biobook.co.kr
Charles River Acquires Two Frontage Bioanalytical Laboratories for $470 Million

Sanofi-Backed Windward Raises $225 Million in IPO to Develop Respiratory Drugs From China

PharmaResearch Reports Third-Quarter Operating Profit of KRW 186.4 Billion, Up 14.7% Year Over Year

Hanmi Pharmaceutical’s Operating Profit Reaches ₩222.6 Billion in First Three Quarters, Up 27.5% Year Over Year

Kolon TissueGene Posts 73.3 Billion Won in Net Income Through Q3, Returns to Profit

BlueMtec Posts 5.5 Billion Won in Net Income Through Q3, Returning to Profit From a Year-Earlier Loss